UK drug delivery device company Bespak, a division of Consort Medical, says that it will develop a nasal delivery device “for a major unnamed global pharmaceutical company.” The contract, Bespak’s first for a nasal device, involves development of a device for an undisclosed product that the pharmaceutical company plans to launch in 2015.
Bespak sells more than 500 million devices every year, according to the company, mostly for injection or oral inhalation, and has manufactured more than 500 million units of the Diskus dry powder inhaler alone. The company has signaled an intention to expand its focus and says that the new contract “is another signal that Bespak Innovations, our new innovations centre based in Cambridge, is delivering on the Company’s strategy to diversify its core competencies of design and high volume manufacture of medical devices into adjacent market areas.”
CEO of Consort Medical, Jon Glenn, commented, “We are delighted to announce our first nasal development contract. With programmes in autoinjectors, Point of Care diagnostics and now nasal applications, Bespak is developing a broad suite of products in new growth markets, de-risking the portfolio.”
Read the Bespak press release.
